VMY-1-103

CAS No. 1209002-43-6

VMY-1-103( VMY 1-103 )

Catalog No. M10779 CAS No. 1209002-43-6

A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    VMY-1-103
  • Note
    Research use only, not for human use.
  • Brief Description
    A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
  • Description
    A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B; increases the sub G(1) fraction of apoptotic cells, induces PARP and caspase-3 cleavage and increases the levels of the death receptors DR4 and DR5, Bax and Bad.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    VMY 1-103
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1209002-43-6
  • Formula Weight
    708.27
  • Molecular Formula
    C34H42ClN9O4S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NCCNS(=O)(C1=C2C=CC=C(N(C)C)C2=CC=C1)=O)C3=CC=C(NC4=C5N=CN(C(C)C)C5=NC(N[C@H](C(C)C)CO)=N4)C=C3Cl
  • Chemical Name
    2-Chloro-N-[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]benzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ringer L, et al. Cancer Biol Ther. 2011 Nov 1;12(9):818-26. 2. Sirajuddin P, et al. Cell Cycle. 2012 Oct 15;11(20):3801-9. 3. Waye S, et al. Aging (Albany NY). 2015 Oct;7(10):854-68.
molnova catalog
related products
  • Ro-3306

    RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.

  • CGP-74514A hydrochlo...

    CGP-74514A hydrochloride is a potent CDK1 inhibitor with IC50 of 25 nM; induces caspase-9 activation and PARP degradation, mediates apoptosis in U937 cells.

  • Ryuvidine

    Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM).